News

Our Navigators are pleased to announce the publication of “Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers” in the latest edition of the New England Journal of Medicine. CirQuest founder and CSO MLM Medical Labs, Dr. Lisa K.

Jennings, worked with trailblazing partners from the Brigham and Women’s Hospital Heart and Vascular Center, Harvard Medical School, Thomas Jefferson University, the Thrombosis and Atherosclerosis Research Institute, and PhaseBio Pharmaceuticals to co-author this fascinating study. Visit NEJM to read the publication.